Dyslipidaemia is an important modifiable risk factor contributing to the increased risk of atherosclerotic cardiovascular disease in diabetes. However, determining when to initiate statin therapy in young adults with type 1 diabetes mellitus (T1DM) can often be challenging. This is due to a relative paucity of data in this area to guide management and for developing T1DM-specific risk engines. Current recommendations from international guidelines offer differing approaches to cardiovascular risk stratification and management of dyslipidaemia in T1DM. We present a clinical vignette and comment on the use of nontraditional methods of cardiovascular risk stratification. The strategy for managing dyslipidaemia in young T1DM should be individualized, and recommendations from guidelines should serve to inform clinical judgement.
| CLINICAL VIGNETTE
A 30-year-old Caucasian female with type 1 diabetes mellitus diagnosed at 12 years of age attends your clinic for routine followup. She is a nonsmoker and is overweight (BMI 27 kg/m 2 ).
Hypoglycaemia is uncommon, and there is no history of hypertension, albuminuria, and microvascular or macrovascular complications. Her only medication is insulin. Her father had a fatal myocardial infarction at 54 years of age. HbA1c is 7.6%, and fasting plasma lipid profile shows total cholesterol of 4.8 mmol/L, low-density lipoprotein cholesterol (LDL-C) of 3.0 mmol/L, high-density lipoprotein cholesterol (HDL-C) of 1.3 mmol/L, and triglycerides of 0.8 mmol/L. She asks you whether she should be on a statin because of diabetes and the risk of heart disease, but is also worried about side effects.
| INTRODUCTION
Diabetes mellitus is an independent risk factor for atherosclerotic cardiovascular disease (CVD). 1 People diagnosed with type 1 diabetes mellitus (T1DM) at a young age have an increased lifetime risk of CVD due to their long duration of diabetes. 1 In addition, dyslipidaemia is an important modifiable factor contributing to accelerated atherosclerosis. Numerous trials have shown that HMG-CoA reductase inhibitors (statins) are beneficial in primary and secondary prevention of CVD in diabetes. 2 However, determining when to initiate statins for primary prevention of CVD in young adults with T1DM is often challenging due to the lack of data in subgroups with T1DM.
| WHAT DO THE GUIDELINES SAY?
There are many guidelines available for managing dyslipidaemia.
However, recommendations for T1DM are largely based on evidence from trials in people with type 2 diabetes mellitus (T2DM) and expert opinion. Guidelines currently recommend treating dyslipidaemia to lipoprotein targets based on risk category (Table 1) 3-6 or recommend initiating statins in at-risk groups (Table 2) . [7] [8] [9] A family history of premature CVD can be considered a major risk factor. The guidelines in Table 1 stratify our patient as high/very high risk, thereby favouring statin use to attain lipoprotein targets.
However, the guidelines in Table 2 recommend statins be considered or offered to our patient.
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| IS THERE GUIDELINE CONSENSUS?
There is variation in guideline recommendations for our patient. This is because the cut-off points used to define risk categories are in part arbitrary. People with diabetes are considered high risk, even in the absence of additional risk factors. However, there is increasing recognition that T1DM is a heterogeneous condition, where some young people may be low/moderate risk. 4 This supports the need to identify low risk individuals, thus preventing overtreatment. Several biomarkers have improved CVD risk prediction beyond traditional methods when used alone or in combination. We briefly discuss preferred methods in the context of our patient.
| Coronary artery calcium scan
Coronary artery calcium scores are used as a surrogate measure of coronary atherosclerosis. A score of 0 Agatston units can reliably stratify our patient as low risk in the short term. 10 Statin initiation 
| Microalbuminuria
Microalbuminuria is strongly associated with an increased risk of CVD in people with T1DM and is regarded as a major CVD risk factor. [3] [4] [5] [6] 8, 9 Albuminuria is thought to be a marker of systemic vascular damage, and transcapillary leakage of lipoproteins may play a role in accelerating atherosclerosis. 11 CVD risk for any given plasma concentration of lipoproteins may be higher in this setting. Therefore, monitoring for microalbuminuria is important for our patient.
| High-sensitivity C-reactive protein
High-sensitivity C-reactive protein (hs-CRP) is an inflammatory marker that is associated with CVD events. 5 hs-CRP should be measured on multiple occasions and should not be measured when unwell. 3 Concentrations <1.0 mg/L are normal, while >3.0 mg/dL is considered high risk. 5 Studies in people with diabetes have confirmed the relationship between elevated hs-CRP and CVD; however; risk prediction using hs-CRP was only marginally improved. 12 In addition, lipoprotein-associated phospholipase is an enzyme that hydrolyzes oxidized phospholipids and is a marker of atherogenic vascular inflammation. 5 Elevated measures in our patient may support statin use.
| Lipoprotein(a)
Lipoprotein(a) is genetically determined and is independently associated with risk of CVD. [3] [4] [5] [6] Measurement of lipoprotein(a) can be considered in people at high or borderline-high risk, or who have a strong family history of CVD. 4 An elevated concentration may stratify our patient as high risk, thus favouring statin use. 13 Concentrations >0.5 g/L (80th percentile) in the general population may confer significant risk, although in T1DM, there is data to suggest significant risk when >0.3 g/L. 3, 4, 13 An inverse relationship between lipoprotein(a) and incidence of diabetes may exist. 13 Further research is required to assess the epidemiology of lipoprotein(a) in T1DM, optimal cut-off values for risk stratification, and the role of lipoprotein(a)-lowering therapies. 13 
| Others to consider
Other markers of subclinical atherosclerosis that are not widely used for risk stratification include ankle-brachial index (preexercise and postexercise) and carotid artery intima-media thickness using ultrasonography. 4, 5 Furthermore, detecting hypertension by ambulatory blood pressure monitoring or early retinopathy by retinal photography and retinal artery dimensions may be helpful. A discussion on all risk stratification methods is beyond the scope of this commentary.
| WHAT OTHER PATIENT FACTORS SHOULD BE CONSIDERED?
There is a perception that statin use will result in side effects.
Adequately addressing the benefits and risks of statins may improve adherence. Side effects were rare in large double-blind placebocontrolled trials. 14 It may be worthwhile gauging the patient's understanding and perceived risk. Furthermore, the potential for medication interactions, cost, and future pregnancy should be considered.
| ARE THERE OTHER LIPID-LOWERING OPTIONS?
Improving glycaemic control can improve lipid profiles in T1DM. 1 However, statins may still be required for CVD risk reduction. In addition, all guidelines recommend lifestyle modifications.
Phytosterols can be considered as an adjunct therapy. These are naturally occurring compounds that reduce LDL-C by 7% to 10% at dosages of 2 g/day. 4 However, their effects on CVD outcomes are unproven. 
